Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

PZ0356

Sigma-Aldrich

PF-06291874

≥98% (HPLC)

Synonym(s):

N-[4-[(1S)-1-[3,5-Dimethyl-4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenoxy]butyl]benzoyl]--alanine

Sign Into View Organizational & Contract Pricing

Select a Size

5 MG
$102.60
25 MG
$436.00

$102.60

List Price$108.00Save 5%
Web-Only Promotion
Check Cart for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
5 MG
$102.60
25 MG
$436.00

About This Item

Empirical Formula (Hill Notation):
C26H28F3N3O4
CAS Number:
1393124-08-7
Molecular Weight:
503.51
MDL number:
MFCD30343861
UNSPSC Code:
51111800
NACRES:
NA.77

$102.60

List Price$108.00Save 5%
Web-Only Promotion
Check Cart for Availability
Request a Bulk Order

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

room temp

SMILES string

FC(F)(F)c1c[n](nc1)c2c(cc(cc2C)O[C@@H](CCC)c3ccc(cc3)C(=O)NCCC(=O)O)C

InChI key

IBDYYOQKQCCSDP-QFIPXVFZSA-N

Biochem/physiol Actions

PF-06291874 is an orally active, potent and selective glucagon receptor antagonist. PF-06291874 exhibits a robust glucose reductions in subjects with type 2 diabetes mellitus.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
037M4724V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Esther C Y Lee et al.
Bioorganic & medicinal chemistry letters, 24(3), 839-844 (2014-01-15)
Identification of orally active, small molecule antagonists of the glucagon receptor represents a novel treatment paradigm for the management of type 2 diabetes mellitus. The present work discloses novel glucagon receptor antagonists, identified via conformational constraint of current existing literature
Arthur Bergman et al.
Diabetes research and clinical practice, 126, 95-104 (2017-02-27)
The glucagon receptor antagonist PF-06291874 has demonstrated robust glucose reductions in subjects with type 2 diabetes mellitus (T2DM) on background metformin. This study assessed the pharmacokinetics, pharmacodynamics, safety, and tolerability of PF-06291874 administered as monotherapy in subjects with T2DM. After

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service